GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipsen SA (FRA:I7G) » Definitions » Other Operating Expense

Ipsen (FRA:I7G) Other Operating Expense : €421 Mil (TTM As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Ipsen Other Operating Expense?

Ipsen's Other Operating Expense for the six months ended in Dec. 2023 was €205 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was €421 Mil.

Ipsen's quarterly Other Operating Expense declined from Dec. 2022 (€217 Mil) to Jun. 2023 (€185 Mil) but then increased from Jun. 2023 (€185 Mil) to Dec. 2023 (€205 Mil).

Ipsen's annual Other Operating Expense increased from Dec. 2021 (€116 Mil) to Dec. 2022 (€273 Mil) and increased from Dec. 2022 (€273 Mil) to Dec. 2023 (€391 Mil).


Ipsen Other Operating Expense Historical Data

The historical data trend for Ipsen's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ipsen Other Operating Expense Chart

Ipsen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 132.90 93.90 115.90 273.00 390.70

Ipsen Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 56.50 216.50 185.40 205.30 215.80

Ipsen Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €421 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ipsen Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Ipsen's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Ipsen Business Description

Traded in Other Exchanges
Address
65 Quai Georges Gorse, Billancourt Cedex, Boulogne, FRA, 92100
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.

Ipsen Headlines

No Headlines